{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T15:55:06Z","timestamp":1781366106289,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ege University Scientific Research Coordination","award":["23998"],"award-info":[{"award-number":["23998"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Urotensin-II is a powerful vasoconstrictor peptide. Both the peptide and its receptor, GPR14, affect central nervous system, cardiovascular system, and kidney functions. Urotensin-II was found to be involved in the development of many solid organ tumors. The peptide and its receptor have been demonstrated to be present in breast cancer tissue. Moreover, its human plasma level is increased in breast cancer patients. It has also been reported that some cancer patients may have urotensin gene polymorphisms. Antagonists of this peptide receptor with different chemical structures have been produced and studied in different disease models. There are no experimental or clinical studies investigating the effects of urotensin-II receptor antagonists on breast cancer. In this study, MCF-7 cells were grown in an appropriate environment and then plated in wells. WST-8 was used to detect cell proliferation and inhibition effects. The expression levels of the MTA-1, ESR1, Kiss1, UT-II and UTR genes were measured via quantitative RT\u2012PCR. This study is the first to show the effects of urotensin-II peptide and its receptor antagonists on breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>While urotensin-II increased cell proliferation, all the antagonists had inhibitory effects. When the expression of genes affecting the metastasis or suppression of tumor cells was investigated, urotensin-II increased MTA-1 and ESR1 expression and decreased Kiss1 expression. Urotensin-II receptor antagonists reversed these effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>As a result, while urotensin-II triggered breast cancer cell proliferation, its receptor antagonists had inhibitory effects on proliferation and positive regulatory effects on tumor suppressor genes. These results suggest that urotensin-II receptor antagonists may provide effective results for breast cancer treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00366-7","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T15:00:24Z","timestamp":1781362824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In-vitro effects of the urotensin-II peptide and its receptor antagonists on mcf-7 breast cancer cell line"],"prefix":"10.1186","volume":"38","author":[{"given":"Murat","family":"Olukman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi","family":"Olukman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kutay","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"B\u00f6l\u00fck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunde Y\u0131lmaz","family":"S\u00fcsl\u00fcer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Erol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"366_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s00540-007-0524-z","volume":"21","author":"J McDonald","year":"2007","unstructured":"McDonald J, Batuwangala M, Lambert DG. Role of urotensin II and its receptor in health and disease. J Anesth. 2007;21:378\u201389. https:\/\/doi.org\/10.1007\/s00540-007-0524-z.","journal-title":"J Anesth"},{"key":"366_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1568009616666160621101248","volume":"16","author":"A Federico","year":"2016","unstructured":"Federico A, Zappavigna S, Dallio M, Misso G, Francesco Merlino, Loguercio C, Novellino E, Grieco P, Caraglia M. Urotensin-II Receptor: A double identity receptor involved in vasoconstriction and in the development of digestive tract cancers and other tumors. Curr Cancer Drug Targets. 2016;16:1\u201313. https:\/\/doi.org\/10.2174\/1568009616666160621101248.","journal-title":"Curr Cancer Drug Targets"},{"key":"366_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/ijms242115625","volume":"24","author":"MK Ibragimova","year":"2023","unstructured":"Ibragimova MK, Tsyganov MM, Kravtsova EA, Tsydenova IA, Litviakov NV. Organ-specificity of breast cancer metastasis. Int Mol Sci. 2023;24:2\u201315. https:\/\/doi.org\/10.3390\/ijms242115625.","journal-title":"Int Mol Sci"},{"key":"366_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10555-019-09814-4","volume":"38","author":"IV Ulasov","year":"2019","unstructured":"Ulasov IV, Borovjagin AV, Timashev P, Cristofanili M, Welch DR. KISS1 in breast cancer progression and autophagy. Cancer Metastasis Rev. 2019;38:493\u2013506. https:\/\/doi.org\/10.1007\/s10555-019-09814-4.","journal-title":"Cancer Metastasis Rev"},{"key":"366_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.12659\/MSM.890459","volume":"20","author":"O Balakan","year":"2014","unstructured":"Balakan O, Kalender ME, Suner A, Cengiz B, Oztuzcu S, Bayraktar R, Borazan E, Babacan T, Camci C. The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer. Med Sci Monit. 2014;20:1419\u201325. https:\/\/doi.org\/10.12659\/MSM.890459.","journal-title":"Med Sci Monit"},{"key":"366_CR6","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1007\/s13277-015-3082-2","volume":"36","author":"O Yumrutas","year":"2015","unstructured":"Yumrutas O, Oztuzcu S, B\u00fcy\u00fckhatipoglu H, Bozgeyik I, Bozgeyik E, Igci YZ, Bagis H, Cevik OM, Kalender ME, Eslik Z, Arslan A. The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer. Tumor Biol. 2015;36:4427\u201332. https:\/\/doi.org\/10.1007\/s13277-015-3082-2.","journal-title":"Tumor Biol"},{"key":"366_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/ijms23042288","volume":"23","author":"KH Lau","year":"2022","unstructured":"Lau KH, Tan AM, Shi Y. New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci. 2022;23:2\u201320. https:\/\/doi.org\/10.3390\/ijms23042288.","journal-title":"Int J Mol Sci"},{"key":"366_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr2889","volume":"13","author":"LD Holliday","year":"2011","unstructured":"Holliday LD, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:1\u20137. https:\/\/doi.org\/10.1186\/bcr2889.","journal-title":"Breast Cancer Res"},{"key":"366_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.molonc.2010.04.004","volume":"4","author":"B Weigelta","year":"2010","unstructured":"Weigelta B, Geyerb FC, Reis-Filhob JS. Histological types of breast cancer: How special are they? Mol Oncol. 2010;4:192\u2013208. https:\/\/doi.org\/10.1016\/j.molonc.2010.04.004.","journal-title":"Mol Oncol"},{"key":"366_CR10","doi-asserted-by":"publisher","unstructured":"Kamala A, Mohsenb A, Kamal A, Siamd I Study of the association between Urotensin 2 (p.T21M and p.S89N) variants and breast cancer in Egyptian patients. Gene Rep. 2020;20. https:\/\/doi.org\/10.1016\/j.genrep.2020.100789.","DOI":"10.1016\/j.genrep.2020.100789"},{"key":"366_CR11","doi-asserted-by":"publisher","first-page":"61152","DOI":"10.18632\/oncotarget.10748","volume":"7","author":"AA Goldberg","year":"2016","unstructured":"Goldberg AA, Joung KB, Mansuri A, Kang Y, Echavarria R, Nikolajev L, Sun Y, Yu JJ, Laporte SA, Schwertani A, Kristof AS. Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2. Oncotarget. 2016;7:61152\u201365. https:\/\/doi.org\/10.18632\/oncotarget.10748.","journal-title":"Oncotarget"},{"key":"366_CR12","doi-asserted-by":"publisher","unstructured":"Wang H, Tang Y, Yang X, Wang W, Han P, Zhao J, He S, Liu P. A crucial angiogenesis-associated gene meox2 could be a promising biomarker candidate for breast cancer. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.759300.","DOI":"10.3389\/fonc.2022.759300"},{"key":"366_CR13","doi-asserted-by":"publisher","unstructured":"Rui-An Wan MTA1 a stress response protein: a master regulator of gene expression and cancer cell behavior. Cancer Metastasis Rev. 2014;33. https:\/\/doi.org\/10.1007\/s10555-014-9525-1.","DOI":"10.1007\/s10555-014-9525-1"},{"key":"366_CR14","doi-asserted-by":"publisher","unstructured":"Hannafon BN, Gin AL, Xu YF, Bruns M, Calloway CL, Ding WQ Metastasis-associated protein 1 (MTA1) is transferred by exosomes and contributes to the regulation of hypoxia and estrogen signaling in breast cancer cells. Cell Communication Signal. 2019;17. https:\/\/doi.org\/10.1186\/s12964-019-0325-7.","DOI":"10.1186\/s12964-019-0325-7"},{"key":"366_CR15","doi-asserted-by":"publisher","first-page":"106526","DOI":"10.1016\/j.jsbmb.2024.106526","volume":"242","author":"FL Monteiro","year":"2024","unstructured":"Monteiro FL, Stepanauskaite L, Archer A, Williams C Estrogen receptor beta expression and role in cancers. J Steroid Biochem Mol Biology. 2024;242:106526. https:\/\/doi.org\/10.1016\/j.jsbmb.2024.106526.","journal-title":"J Steroid Biochem Mol Biology"},{"key":"366_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ctrv.2008.05.007","volume":"34","author":"A Makri","year":"2008","unstructured":"Makri A, Pissimissis N, Lembessis P, Polychronakos C, Koutsilieris M. The kisspeptin (KiSS-1)\/GPR54 system in cancer biology. Cancer Treat Rev. 2008;34:682\u201392. https:\/\/doi.org\/10.1016\/j.ctrv.2008.05.007.","journal-title":"Cancer Treat Rev"},{"key":"366_CR17","doi-asserted-by":"publisher","unstructured":"Blake A, Dragan M, Tirona RG, Hardy DB, Brackstone M, Tuck AB, Babwah AV Bhattacharya M. G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance. Sci Rep. 2017;7. https:\/\/doi.org\/10.1038\/srep46525.","DOI":"10.1038\/srep46525"},{"key":"366_CR18","first-page":"1401","volume":"34","author":"E Papao\u0131conomou","year":"2014","unstructured":"Papao\u0131conomou E, Lymper\u0131 M, Petrak\u0131 C, Ph\u0131l\u0131ppou A, Msaouel P, M\u0131chalopoulou F, Kaf\u0131r\u0131 G, Vass\u0131lakos G, Zografos G. M\u0131chael Kouts\u0131l\u0131er\u0131s. Kiss-1\/GPR54 protein expression in breast cancer. Anticancer Res. 2014;34:1401\u20138.","journal-title":"Anticancer Res"},{"key":"366_CR19","doi-asserted-by":"publisher","unstructured":"Nassour H, Iddir M, Chatenet D Toward targeting the urotensinergic system: overview and challenges. Trends Pharmacol Sci. 2019;40. https:\/\/doi.org\/10.1016\/j.tips.2019.08.005.","DOI":"10.1016\/j.tips.2019.08.005"},{"key":"366_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2011.00038","volume":"2","author":"P Tsoukas","year":"2011","unstructured":"Tsoukas P, Kan \u00c9, Adel Giaid A Potential clinical implications of the urotensinII receptor antagonists. Front Pharmacol. 2011;2:1\u201311. https:\/\/doi.org\/10.3389\/fphar.2011.00038.","journal-title":"Front Pharmacol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00366-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00366-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00366-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T15:00:26Z","timestamp":1781362826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00366-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00366-7","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ege University Medical Research Ethics Committee, numbered E.3058652, stated that this manuscript does not require ethical committee approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}